News
Are SGLT2 Inhibitors Only Suitable for the Treatment of Diabetes?
SGLT2 inhibitors, or gliflozins, are effective antidiabetic drugs that have shown nephroprotective and cardioprotective effects in diabetics, repeatedly demonstrated in clinical trials. At the European Cardiology Congress in September 2019 in Paris, results were presented from the DAPA-HF study, where dapagliflozin became the first SGLT2 inhibitor to show benefits in patients with heart failure with reduced ejection fraction of the left ventricle, regardless of whether they had type 2 diabetes or not. The study thus offered a completely new…
How to Manage Thromboprophylaxis in Obese and Extremely Obese Patients?
Doctors often address the question of how to dose thromboprophylaxis in overweight individuals. The…
Positive Effect of Pregabalin Not Only on Neuropathic Pain in Patients with Spinal Cord Injury
Spinal cord injury is often accompanied by painful conditions. A study published in the prestigious…
Pregabalin in the Hands of a General Practitioner
A recent Cochrane systematic review by authors from Oxford University examined the effect of…
Can We Lump All Gabapentinoids Together?
General practitioners often encounter peripheral neuropathic pain in their practice. One of the…
Valproate for Acute Mania: Is Practice Really Evidence-Based and Recommended?
Authors from the University of Western Ontario conducted an audit in an acute psychiatric intake…
Low-Molecular-Weight Heparin as Adjuvant Therapy in Small-Cell Lung Cancer − Results of the RASTEN Study
Several studies and meta-analyses in the past have pointed to a possible positive effect of…
Efficacy and Speed of Pain Relief in Rheumatoid Arthritis When Adding Baricitinib to Methotrexate
The phase III clinical trial RA-BEAM conducted in patients with rheumatoid arthritis (RA)…
Can NOACs 'Compete' with Well-Managed Warfarin Treatment? Retrospective Data from Swedish Registers
The efficacy and safety of new oral anticoagulants (NOACs) in stroke prevention in atrial…
Documented Cardiovascular Benefit of Empagliflozin in New American Diabetes Treatment Guidelines
Two leading overseas medical professional societies, the American Diabetes Association (ADA) and the...